Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2021-05-18
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of nintedanib when given
together with capecitabine and to see how well they work in treating patients with colorectal
cancer that has not responded to previous treatment (refractory) and has spread to other
places in the body (metastatic). Nintedanib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. It may also block the growth of new blood vessels
necessary for tumor growth. Drugs used in chemotherapy, such as capecitabine, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving nintedanib with capecitabine
may be a better treatment for colorectal cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
Boehringer Ingelheim National Cancer Institute (NCI) National Comprehensive Cancer Network